ReSPONDINg TACtically, degrading strategically

Breanna L Zerfas; Lyn H Jones

doi:10.1016/j.tips.2023.08.010

ReSPONDINg TACtically, degrading strategically

Trends Pharmacol Sci. 2023 Nov;44(11):753-754. doi: 10.1016/j.tips.2023.08.010. Epub 2023 Sep 7.

Authors

Breanna L Zerfas¹, Lyn H Jones²

Affiliations

¹ Center for Protein Degradation, Dana-Farber Cancer Institute, Boston, MA, USA; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA, USA. Electronic address: breannal_zerfas@dfci.harvard.edu.
² Center for Protein Degradation, Dana-Farber Cancer Institute, Boston, MA, USA; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA, USA. Electronic address: lyn_jones@dfci.harvard.edu.

PMID: 37689534
DOI: 10.1016/j.tips.2023.08.010

Abstract

Targeted protein degradation has become a popular strategy to expand the druggable proteome, but therapeutic options for membrane proteins are limited. Sun et al. have now developed R-spondin chimeras (ROTACs) that effectively mediate lysosomal degradation of PD-L1, thus providing a modular platform that may be applicable to other membrane proteins.

Keywords: membrane proteins; targeted protein degradation.